NantKwest, Inc. stock price

Today's NASDAQ:NK chart, history & news

Price:
32.49 USD
Change:
+0 (0%)
Trade Buy
67% of retail CFD accounts lose money

Key stats

Price open
Previous close 32.49
Market cap 3.55B
Volume 0
Day high 32.49
Day low 32.49
Year high 45.42
Year low 2.52
Year to date change 143.74%
P/E ratio N.A
Company Profile
Fundamentals
Insider Information
News

About NantKwest, Inc.

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

Company information

Company name
NantKwest, Inc.
Exchange
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Patrick Soon-Shiong
Address
3530 John Hopkins Ct, San Diego, California, 92121-1121
Country
United States
Contact information
18586330300
Website
https://www.nantkwest.com/